The global preterm birth and PROM testing market size was accounted for USD 1.55 billion in 2024, grew to USD 1.68 billion in 2025 and is predicted to surpass around USD 3.45 billion by 2034, representing a healthy CAGR of 8.34% between 2025 and 2034. The North America preterm birth and PROM testing market size was calculated at USD 600 million in 2024 and is expected to grow at a fastest CAGR of 8.53% during the forecast year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
7.1. Preterm Birth and PROM Testing Market, by Test Type, 2025-2034
7.1.1. Ultrasound
7.1.1.1. Market Revenue and Forecast (2022-2034)
7.1.2. Biochemical Markers
7.1.2.1. Market Revenue and Forecast (2022-2034)
7.1.3. Pelvic Exam
7.1.3.1. Market Revenue and Forecast (2022-2034)
7.1.4. Nitazine Test
7.1.4.1. Market Revenue and Forecast (2022-2034)
7.1.5. Uterine Monitoring
7.1.5.1. Market Revenue and Forecast (2022-2034)
7.1.6. Pooling
7.1.6.1. Market Revenue and Forecast (2022-2034)
7.1.7. Ferning Test
7.1.7.1. Market Revenue and Forecast (2022-2034)
7.1.8. Others
7.1.8.1. Market Revenue and Forecast (2022-2034)
8.1. Preterm Birth and PROM Testing Market, by End User, 2025-2034
8.1.1. Diagnostic Laboratories
8.1.1.1. Market Revenue and Forecast (2022-2034)
8.1.2. Hospitals
8.1.2.1. Market Revenue and Forecast (2022-2034)
8.1.3. Others
8.1.3.1. Market Revenue and Forecast (2022-2034)
9.1. North America
9.1.1. Market Revenue and Forecast, by Test (2022-2034)
9.1.2. Market Revenue and Forecast, by End User (2022-2034)
9.1.3. U.S.
9.1.3.1. Market Revenue and Forecast, by Test (2022-2034)
9.1.3.2. Market Revenue and Forecast, by End User (2022-2034)
9.1.4. Rest of North America
9.1.4.1. Market Revenue and Forecast, by Test (2022-2034)
9.1.4.2. Market Revenue and Forecast, by End User (2022-2034)
9.2. Europe
9.2.1. Market Revenue and Forecast, by Test (2022-2034)
9.2.2. Market Revenue and Forecast, by End User (2022-2034)
9.2.3. UK
9.2.3.1. Market Revenue and Forecast, by Test (2022-2034)
9.2.3.2. Market Revenue and Forecast, by End User (2022-2034)
9.2.4. Germany
9.2.4.1. Market Revenue and Forecast, by Test (2022-2034)
9.2.4.2. Market Revenue and Forecast, by End User (2022-2034)
9.2.5. France
9.2.5.1. Market Revenue and Forecast, by Test (2022-2034)
9.2.5.2. Market Revenue and Forecast, by End User (2022-2034)
9.2.6. Rest of Europe
9.2.6.1. Market Revenue and Forecast, by Test (2022-2034)
9.2.6.2. Market Revenue and Forecast, by End User (2022-2034)
9.3. APAC
9.3.1. Market Revenue and Forecast, by Test (2022-2034)
9.3.2. Market Revenue and Forecast, by End User (2022-2034)
9.3.3. India
9.3.3.1. Market Revenue and Forecast, by Test (2022-2034)
9.3.3.2. Market Revenue and Forecast, by End User (2022-2034)
9.3.4. China
9.3.4.1. Market Revenue and Forecast, by Test (2022-2034)
9.3.4.2. Market Revenue and Forecast, by End User (2022-2034)
9.3.5. Japan
9.3.5.1. Market Revenue and Forecast, by Test (2022-2034)
9.3.5.2. Market Revenue and Forecast, by End User (2022-2034)
9.3.6. Rest of APAC
9.3.6.1. Market Revenue and Forecast, by Test (2022-2034)
9.3.6.2. Market Revenue and Forecast, by End User (2022-2034)
9.4. MEA
9.4.1. Market Revenue and Forecast, by Test (2022-2034)
9.4.2. Market Revenue and Forecast, by End User (2022-2034)
9.4.3. GCC
9.4.3.1. Market Revenue and Forecast, by Test (2022-2034)
9.4.3.2. Market Revenue and Forecast, by End User (2022-2034)
9.4.4. North Africa
9.4.4.1. Market Revenue and Forecast, by Test (2022-2034)
9.4.4.2. Market Revenue and Forecast, by End User (2022-2034)
9.4.5. South Africa
9.4.5.1. Market Revenue and Forecast, by Test (2022-2034)
9.4.5.2. Market Revenue and Forecast, by End User (2022-2034)
9.4.6. Rest of MEA
9.4.6.1. Market Revenue and Forecast, by Test (2022-2034)
9.4.6.2. Market Revenue and Forecast, by End User (2022-2034)
9.5. Latin America
9.5.1. Market Revenue and Forecast, by Test (2022-2034)
9.5.2. Market Revenue and Forecast, by End User (2022-2034)
9.5.3. Brazil
9.5.3.1. Market Revenue and Forecast, by Test (2022-2034)
9.5.3.2. Market Revenue and Forecast, by End User (2022-2034)
9.5.4. Rest of LATAM
9.5.4.1. Market Revenue and Forecast, by Test (2022-2034)
9.5.4.2. Market Revenue and Forecast, by End User (2022-2034)
10.1. Abbott
10.1.1. Company Overview
10.1.2. Product Offerings
10.1.3. Financial Performance
10.1.4. Recent Initiatives
10.2. Qiagen N.V.
10.2.1. Company Overview
10.2.2. Product Offerings
10.2.3. Financial Performance
10.2.4. Recent Initiatives
10.3. Biosynex
10.3.1. Company Overview
10.3.2. Product Offerings
10.3.3. Financial Performance
10.3.4. Recent Initiatives
10.4. Hologic
10.4.1. Company Overview
10.4.2. Product Offerings
10.4.3. Financial Performance
10.4.4. Recent Initiatives
10.5. Cooper Surgical
10.5.1. Company Overview
10.5.2. Product Offerings
10.5.3. Financial Performance
10.5.4. Recent Initiatives
10.6. Sera Prognostics
10.6.1. Company Overview
10.6.2. Product Offerings
10.6.3. Financial Performance
10.6.4. Recent Initiatives
10.7. Medixbiochemica
10.7.1. Company Overview
10.7.2. Product Offerings
10.7.3. Financial Performance
10.7.4. Recent Initiatives
10.8. IQ Products
10.8.1. Company Overview
10.8.2. Product Offerings
10.8.3. Financial Performance
10.8.4. Recent Initiatives
10.9. NX Prenatal, Inc.
10.9.1. Company Overview
10.9.2. Product Offerings
10.9.3. Financial Performance
10.9.4. Recent Initiatives
10.10. Clinical Innovations, Inc.
10.10.1. Company Overview
10.10.2. Product Offerings
10.10.3. Financial Performance
10.10.4. Recent Initiatives
11.1. Primary Research
11.2. Secondary Research
11.3. Assumptions
12.1. About Us
12.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample